24. Byfavo

medical surgery
The COVID-19 pandemic has raised spot shortages of hospital sedatives used to treat patients, specifically those requiring intubation. (Pixabay)

Active ingredient: Remimazolam
Use: Moderate sedation
Peak sales estimate: N/A
Approved: July 2
Company: Acacia Pharma

The scoop: The COVID-19 pandemic has raised spot shortages of hospital sedatives used to treat patients, specifically those requiring intubation. Amid those chronic shortages, the FDA approved Acacia Pharma’s Byfavo (remimazolam) in July as a short-term sedative for use during invasive medical procedures lasting 30 minutes or less. While that indication won’t benefit intubated patients, the new drug could help fill in hospitals’ shortages during the pandemic. Acacia predicted there were around 25 million invasive procedures undertaken each year in the U.S., around 90% of which require “moderate” sedation. Byfavo was Acacia’s second approved drug after Barhemsys, which earned the FDA’s nod in February. – Kyle Blankenship

24. Byfavo